Factor VIII-East Hartford (arginine 1689 to cysteine) has procoagulant activity when separated from von Willebrand factor
- PMID: 1569181
- PMCID: PMC443006
- DOI: 10.1172/JCI115726
Factor VIII-East Hartford (arginine 1689 to cysteine) has procoagulant activity when separated from von Willebrand factor
Abstract
Factor VIII East Hartford (FVIII-EH) procoagulant activity is reduced because the substitution of cysteine for arginine 1689 abolishes an essential Factor VIII light chain thrombin cleavage site. Incubation of FVIII-EH plasma with penicillamine or DTT causes a five- to sixfold increase in FVIII-EH VIII:C, at 80 and 1 mM, respectively. While there is no FVIII-EH light chain cleavage when thrombin is added in the presence of penicillamine or DTT, these reducing agents disrupt the FVIII-vWf complex. For example, the addition of 5 mM DTT to normal or FVIII-EH plasma causes a 50% reduction in Factor VIII binding to vWf. These observations suggested that DTT increases FVIII-EH VIII:C by partial dissociation of FVIII-EH from vWf. This was verified by showing that vWf-free FVIII-EH had VIII:C activity of 21 U/dl, while the starting plasma level was 2.5 U/dl. Removal of other FVIII-EH plasma proteins by agarose gel filtration had no effect on VIII:C activity. The demonstration that this mutant Factor VIII has cofactor function when separated from vWf indicates that the dissociation of Factor VIII from vWf is an essential effect of Factor VIII light chain cleavage at arginine-1689.
Similar articles
-
Cysteamine enhances the procoagulant activity of Factor VIII-East Hartford, a dysfunctional protein due to a light chain thrombin cleavage site mutation (arginine-1689 to cysteine).J Clin Invest. 1992 May;89(5):1375-81. doi: 10.1172/JCI115725. J Clin Invest. 1992. PMID: 1569180 Free PMC article.
-
Some effects of calcium on the activation of human factor VIII/Von Willebrand factor protein by thrombin.J Clin Invest. 1977 Oct;60(4):819-28. doi: 10.1172/JCI108836. J Clin Invest. 1977. PMID: 408379 Free PMC article.
-
The association of factor VIII with von Willebrand factor.Mayo Clin Proc. 1991 May;66(5):524-34. doi: 10.1016/s0025-6196(12)62395-7. Mayo Clin Proc. 1991. PMID: 1903173 Review.
-
Electron microscopy of human factor VIII/Von Willebrand glycoprotein: effect of reducing reagents on structure and function.J Cell Biol. 1982 Nov;95(2 Pt 1):632-40. doi: 10.1083/jcb.95.2.632. J Cell Biol. 1982. PMID: 6815213 Free PMC article.
-
The factor VIII/von Willebrand factor complex: basic and clinical issues.Haematologica. 2003 Jun;88(6):EREP02. Haematologica. 2003. PMID: 12826528 Review.
Cited by
-
Cysteamine enhances the procoagulant activity of Factor VIII-East Hartford, a dysfunctional protein due to a light chain thrombin cleavage site mutation (arginine-1689 to cysteine).J Clin Invest. 1992 May;89(5):1375-81. doi: 10.1172/JCI115725. J Clin Invest. 1992. PMID: 1569180 Free PMC article.
-
The 3.2 Å structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain.J Thromb Haemost. 2020 Jan;18(1):57-69. doi: 10.1111/jth.14621. Epub 2019 Sep 8. J Thromb Haemost. 2020. PMID: 31454152 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous